BIOTRONIK Lumax DR ICD Series, Technical Manual, Page: 57 / 176

Lumax Technical Manual 49
If the patient’s condition permits, use exercise stress testing to do
the following:
•
Determine the maximum rate of the patient’s normal
rhythm.
•
Identify any supraventricular tachyarrhythmias.
•
Identify exercise-induced tachyarrhythmias.
The maximum exercise rate or the presence of supraventricular
tachyarrhythmias may influence selection of programmable
parameters. Holter monitoring or other extended ECG monitoring
also may be helpful.
If the patient is being treated with antiarrhythmic or cardiac drugs,
the patient should be on a maintenance drug dose rather than a
loading dose at the time of pulse generator implantation. If
changes to drug therapy are made, repeated arrhythmia
inductions are recommended to verify pulse generator detection
and conversion. The pulse generator also may need to be
reprogrammed.
Changes in a patient’s antiarrhythmic drug or any other
medication that affect the patient’s normal cardiac rate or
conduction can affect the rate of tachyarrhythmias and/or efficacy
of therapy.
If another cardiac surgical procedure is performed prior to
implanting the pulse generator, it may be preferable to implant the
lead system at that time. This may prevent the need for an
additional thoracic operation.
1.7.2 Specific Patient Populations
Pregnancy - If there is a need to image the device, care should
be taken to minimize radiation exposure to the fetus and the
mother.
Nursing Mothers - Although appropriate biocompatibility testing
has been conducted for this implant device, there has been no
quantitative assessment of the presence of leachables in breast
milk.